Hostname: page-component-8448b6f56d-t5pn6 Total loading time: 0 Render date: 2024-04-19T10:49:33.968Z Has data issue: false hasContentIssue false

Differences in the prescribing of medication for physical disorders in individuals with v. without mental illness: meta-analysis

Published online by Cambridge University Press:  02 January 2018

Alex J. Mitchell*
Department of Psycho-oncology, Leicestershire Partnership Trust and Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK
Oliver Lord
Crisis Resolution and Home Treatment Team, Leicestershire Partnership Trust, Leicester, UK
Darren Malone
Older People Mental Health Services, Lakes District Health Board, New Zealand
Alex J. Mitchell, MRCPsych, Department of Psycho-oncology, Leicestershire Partnership Trust, Leicester LE5 0TD, UK. Email:
Rights & Permissions [Opens in a new window]



There is some concern that patients with mental illness may be in receipt of inferior medical care, including prescribed medication for medical conditions.


We aimed to quantify possible differences in the prescription of medication for medical conditions in those with v. without mental illness.


Systematic review and random effects meta-analysis with a minimum of three independent studies to warrant pooling by drug class.


We found 61 comparative analyses (from 23 publications) relating to the prescription of 12 classes of medication for cardiovascular health, diabetes, cancer, arthritis, osteoporosis and HIV in a total sample of 1931 509 people, in those with severe mental illness the adjusted odds ratio (OR) for an equitable prescription was 0.74 (95% CI 0.63-0.86), with lower than expected prescriptions for angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (ACE/ ARBs), beta-blockers and statins. People with affective disorder had an odds ratio of 0.75 (95% CI 0.55-1.02) but this was not significant. Individuals with a history of other (miscellaneous) mental illness had an odds ratio of 0.95 (95% CI 0.92-0.98) of comparable medication with lower receipt of ACE/ARBs but not highly active antiretroviral therapy (HAART) medication. Results were significant in both adjusted and unadjusted analyses.


Individuals with severe mental illness (including schizophrenia) appear to be prescribed significantly lower quantities of several common medications for medical disorders, largely for cardiovascular indications, although further work is required to clarify to what extent this is because of prescriber intent.

Review Article
Copyright © Royal College of Psychiatrists, 2012 

National guidelines from several countries are agreed that the medical care of patients with mental disorders is of paramount importance. Reference Unützer, Schoenbaum, Druss and Katon1Reference Ruiz, Garcia, Ruiloba, Giner Ubago and Garc$lAa-Portilla González5 Yet, serious concerns have been raised about the quality of medical (and screening) services offered to patients with severe mental illness. Reference Mitchell, Malone and Carney Doebbeling6 Individuals with schizophrenia receive as little as half of the monitoring offered to people without schizophrenia in some studies. Reference Roberts, Roalfe, Wilson and Lester7 Further, there is evidence that people with severe mental illness receive suboptimal treatment for established medical conditions. Reference Vahia, Diwan, Bankole, Kehn, Nurhussein and Ramirez8,Reference Desai, Rosenheck, Druss and Perlin9 These disparities in treatment exist in some of the most critical areas of patient care such as general medicine, cardiovascular and cancer care. Reference Mateen, Jatoi, Lineberry, Aranguren, Creagan and Croghan10 This is particularly concerning given that people with schizophrenia appear to have higher rates of post-operative complications, Reference Li, Glance, Cai and Mukamel11 higher post-operative mortality Reference Copeland, Zeber, Pugh, Mortensen, Restrepo and Lawrence12 and higher than expected non-suicide-related mortality. Reference Saha, Chant and McGrath13 Indeed, the physical health of individuals with severe mental illness is poorer than the general population. Reference Prince, Patel, Saxena, Maj, Maselko and Phillips14,Reference Mitchell and Malone15 Looking at comorbidity in more detail shows that individuals with schizophrenia have higher rates of hypothyroidism, dermatitis, eczema, obesity, epilepsy, viral hepatitis, diabetes (type 2), essential hypertension, chronic obstructive pulmonary disease and fluid/electrolyte disorders. Reference Carney, Jones and Woolson16,Reference Weber, Cowan, Millikan and Niebuhr17 Patients with bipolar I disorder also have higher rates of arthritis, hypertension, gastritis, angina and stomach ulcer. Reference Perron, Howard, Nienhuis, Bauer, Woodward and Kilbourne18 The presence of these medical comorbidities adversely affects not just quality of life but also recovery from the underlying psychiatric disorder, Reference Kisely and Simon19 length of hospital admissions Reference Zolnierek20 and paradoxically the likelihood of being offered psychotropic medication. Reference Chwastiak, Rosenheck and Leslie21

Patients with severe mental illness are also at risk of receiving less than adequate preventive services such as medical screening procedures. Medical screening is important not just for the reduction in future morbidity but also low receipt of preventive care is associated with lower quality of life. Reference Mackell, Harrison and McDonnell22 Lord et al recently reviewed studies that examined preventive care in individuals with v. without psychiatric illness. Reference Lord, Mitchell and Malone23 For those individuals with schizophrenia, eight of nine analyses showed inferior preventive care in several areas including in relation to osteoporosis screening, blood pressure monitoring, vaccinations, mammography and cholesterol monitoring. Reference Lord, Mitchell and Malone23 Although many of these chronic conditions may be unavoidable given our current state of knowledge, many deaths in those with mental illness appear to be avoidable. Reference Amaddeo, Barbui, Perini, Biggeri and Tansella24 Unfortunately, medical disorders are often overlooked by mental health specialists in psychiatric settings and by physicians in primary care and medical settings. As a result up to half of all chronic conditions may go unrecognised in severe mental illness. Reference Kilbourne, McCarthy, Welsh and Blow25Reference Bernardo, Banegas, Canas, Casademot, Riesgo and Varela29 In addition, many people with mental ill health who have an unmet need for medical care also have other risk factors for poor treatment such as low income, social isolation, homelessness, substance misuse and lack of healthcare insurance. Reference Desai and Rosenheck30

Given these numerous concerns regarding quality of medical care, elevated mortality and low receipt of preventive services for people with a psychiatric disorder, we undertook a data synthesis of comparative studies that have examined the adequacy of medication prescribing for existing physical disorders in individuals with and without severe mental illness. To the best of our knowledge this is the first meta-analysis using prescribing data in mental ill health groups.


Search and appraisal

A review strategy and extraction sheet was agreed according to the PRISMA standard. We decided to focus on non-organic psychiatric disorders, thus excluding studies pertaining to delirium or dementia. Reference Muther, Abholz, Wiese, Fuchs, Wollny and Pentzek31 We searched Medline/PubMed and Embase abstract databases from inception to November 2010. The initial search strategy is listed in the online supplement. We included any study (observational/interventional) that had measured the prescription or receipt of medication for medical conditions in patients with and without defined mental illness. Four full-text collections were searched: Science Direct, Ingenta Select, Springer-Verlag's LINK and Blackwell-Wiley. In these online databases the same search terms were used but as a full-text search and as a citation search. The abstract databases Web of Knowledge and Scopus were searched, using the terms in the online supplement as a text-word search, and using key papers in a reverse citation search. Finally, a number of journals were hand-searched (British Journal of Psychiatry, Schizophrenia Research, Schizophrenia Bulletin, Psychological Medicine, Acta Psychiatrica Scandavica, American Journal of Psychiatry, Archives of General Psychiatry, Canadian Journal of Psychiatry, Journal of Psychiatric Research, Psychiatric Services, The Psychiatrist (previously known as Psychiatric Bulletin); all from 2000) and several experts contacted. Using this strategy we identified 84 primary data publications and of these 61 reported aspects of quality of medical care other than prescribed medication. Several were excluded due to lack of extractable data despite attempts to find data from the original authors. Reference Cook, Grey, Burke-Miller, Cohen and Anastos32 Data were extracted by two authors (O.L. and A.J.M.) and independently checked by a third (D.F.) (see online supplement). Appraisal of individual studies was performed and the Newcastle-Ottawa evaluation scale for observational studies was used. Reference Wells, Shea, O'Connell, Peterson, Welch, Losos and Tugwell33 In addition, we performed a PRISMA evaluation of our meta-analysis using a standard checklist of 27 items that ensure the quality of a systematic review or meta-analysis. Reference Moher, Liberati, Tetzlaff and Altman34 The Newcastle-Ottawa evaluation scale is a specific set of nine items used to evaluate individual studies. All medication listed in each publication was fully extracted to avoid meta-analytic bias resulting in 61 drug-level analyses.


From the available data, we entered or calculated odds ratios (OR) and r values. We extracted data on the rate of prescribed medication is those with v. without mental illness. Relative risks (hazard ratios) were converted into odds ratios with reference to the reported control event rate, an adaption of a method described elsewhere. Reference Zhang and Yu35 We then used a summary meta-analysis, pooling odds ratios. We attempted to account for potential confounders but these were variably handled by primary studies. We therefore extracted and stratified results into adjusted and unadjusted analysis and specified types of adjustment. Confidence intervals were obtained from all studies or calculated from the data provided. Between-study heterogeneity was assessed using the I 2 statistic. Reference Higgins, Thompson, Deeks and Altman36 Heterogeneity was reduced by stratifying by either type of mental illness or drug class or type of medical condition. Where heterogeneity (defined by >80% I 2) was high, random-effects meta-analysis was preferred otherwise fixed-effects meta-analysis was used. We applied a minimum data-set rule, namely we required a minimum of three independent studies to justify pooling by individual drug class, a convention advised by a number of statistical programs such as STATA. Statsdirect version 2.7.7 for Windows was used to pool studies using the DerSimonian-Laird method for random-effects meta-analysis. Potential study bias was examined using Kendall's tau and Egger bias statistics, Reference Peters, Sutton, Jones, Abrams and Rushton37 but no evidence of publication bias was detected (see online supplement). In order to offer a qualitative interpretation of quantitative data we defined the following grades of treatment adequacy a priori with reference to the comparator population rates: <80% ‘inadequate’; ⩾80% <90% ‘suboptimal’; ⩾90% <95% ‘inequitable’; and ⩾95% ‘adequate’.


Our search identified 61 drug-level analyses regarding prescribing adequacy in 23 publications Reference Baxter, Samnaliev and Clark38Reference Yun, Maravi, Kobayashi, Barton and Davidson60 involving 1 931 509 patients (study-level results shown in online Table DS1; overview of search results shown in Fig. 1). Subgroups included 13 analyses (36 drug-level comparisons) in patients with severe mental illness, 8 analyses (13 comparisons) in patients with affective disorder and 7 analyses (12 comparisons) for other miscellaneous mental illness groups. We used British National Formulary (BNF) codes to classify medications ( In total, there were 12 classes of medication in the analysis: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (ACE inhibitors/ARBs, BNF and, nitroglycerine (BNF 2.6.1), anti-inflammatory medication for arthritis (BNF 4.7.1), antiplatelet drugs (BNF 2.9), anticoagulants (BNF 2.8), beta-blockers (BNF 2.4), cytotoxic chemotherapy (BNF 8.1), insulin (BNF 6.1.1), highly active antiretroviral therapy (HAART, BNF 5.3.1), lipid-regulating drugs (includes statin and non-statins, BNF 2.12) and medication for osteoporosis (largely hormone replacement therapy (HRT), BNF Thus, most were for cardiovascular health indications. We evaluated the quality of studies using the Newcastle-Ottawa criteria (online Table DS2). Using these nine domains we rated 2 studies as having a low overall quality, 12 as having moderate overall quality and 9 with high overall quality but all were considered sufficient for analysis.

Severe mental illness (including schizophrenia)

There were 36 analyses of drug prescribing from a combined pool of over 1.5 million individuals (Fig. 2). The pooled odds ratio for equitable prescribing was 0.74 (95% CI 0.63–0.86) favouring non-mental ill health. I 2 was 97.2 suggesting high heterogeneity. Lower than expected receipt of medication was in evidence for ACE/ARBs (OR = 0.89, 95% CI 0.81–0.98, P = 0.02), beta-blockers (OR = 0.90, 95% CI 0.84–0.96, P = 0.001) and statins (OR = 0.61, 95% CI 0.39–0.94, P = 0.02) but not for anticholesterol drugs in general (statins and non-statins combined), or for anticoagulants (aspirin and non-aspirin combined). However, for non-aspirin anticoagulants alone (clopidogrel and ticlopidine) there was a significantly lower rate (OR = 0.74, 95% CI 0.56–0.97, P = 0.02). Results were similar when stratified by schizophrenia alone. For schizophrenia alone the pooled odds ratio across all medication was 0.69 (95% CI 0.57–0.83, P<0.0001).

Affective disorder

Across 13 analyses involving 232 882 individuals the I 2 was 94.6%. The combined meta-analysis showed a trend towards low receipt with a pooled odds ratio of 0.75 (95% CI 0.55–1.02, P = 0.07), which was significant in fixed-effect but not random-effects analysis (Fig. 3). Lower receipt of medication was evident for beta-blockers (OR = 0.76, 95% CI 0.45–1.29) and lipid-regulating drugs (OR = 0.92, 95% CI 0.64–1.32), but neither were statistically significant. There was inadequate data to examine other classes of medication.

Other mental illness

Across 12 analyses (involving 19 637 individuals with mental illness from a sample of 188 627) the I 2 was 64.5%, suggesting low heterogeneity and permitting fixed-effects analysis. The combined pooled odds ratio was 0.95 (95% CI 0.92–0.98, Fig. 4). Lower receipt of medication was evident for ACE or ARBs (OR = 0.92, 95% CI 0.85–0.99) but not HAART medication (OR = 0.98, 95% CI 0.75–1.28). There was inadequate data to examine other classes of medication.

FIG. 1 Quorom overview of search results.

ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; HRT, hormone replacement therapy; HAART, highly active antiretroviral therapy. a. Classes usually combined by convention.

A summary of results is shown in Table 1.


Main findings

We found 61 comparative analyses relating to the prescription of 12 classes of medication including lipid-regulating agents (includes statins), beta-blockers, antiplatelet and anticoagulant drugs, ACE/ARBs, insulin, cytotoxic chemotherapy, anti-inflammatories, HRT for osteoporosis and HAART for HIV. Patients with severe mental illness had an odds ratio of 0.74 (95% CI 0.63–0.86) for a comparable medication prescription. The differences were found largely in drugs for cardiovascular indications. For example, patients with severe mental illness received lower than expected prescriptions for ACE/ARBs, beta-blockers and statins. Combining all types of mental illness and all classes of drug suggested that patients with any type of mental illness had an odds ratio of 0.78 (95% CI 0.73–0.84, P = 0.0001) of comparable medication (data not shown). Given a typical control event rate (i.e. receipt of medication in the comparison group) of 70%, the actual rate of undertreatment can be estimated at 8% (95% CI 5–12) in those with other mental illness, 10% in those with severe mental illness and 12% in schizophrenia, a disparity that could be classified as ‘inequitable’ or ‘suboptimal’ receipt of medication according to our a priori definition.


Several limitations should be acknowledged. First, we had no a priori protocol for this study but attempted to follow the review strategy suggested in the PRISMA standard. Heterogeneity was found in 5 out of 11 main analyses (Table 1) and this had the effect of rendering the odds ratios observed for affective disorders non-significant. We used the Newcastle-Ottawa scale, which is only one of several possible methods. Reference Stang61 In two studies involving HAART there was no adjustment made for demographic, illness or prescribing variables Reference Mijch, Burgess, Judd, Grech, Komiti and Hoy51,Reference Yun, Maravi, Kobayashi, Barton and Davidson60 (see Table DS1) and therefore these data should be interpreted with caution. Without adjustment it is possible that the group with mental illness had more severe physical illness than the comparison group – although this should of course favour higher rates of prescribing, not lower rates. One study reported hazard ratios with no control event rate, Reference Himelhoch, Moore, Treisman and Gebo46 therefore we estimated the control event rate using data from related publications from the same group (pending confirmation from the authors). Another limitation is that the definition of mental illness, particularly severe mental illness varied considerably between studies, with seven studies defining mental illness using routine clinical interviews and one using prescription of haloperidol as a marker of mental ill health. The remaining studies used ICD-9 coding. A further important limitation is that most studies specified only that the mental health diagnosis was present in the year preceding the prescription of medication and therefore concurrent mental illness, symptoms of mental illness and severity of mental illness cannot be adequately reported. We also note that although the majority of disparities were manifest in drugs prescribed for cardiovascular conditions, the sample size was modest for most other medical conditions. We also note that in all but 1 of the 23 studies the setting was a country where health insurance is operating (largely USA), as opposed to socialised healthcare. Further studies should examine potential prescribing inequalities in countries with nationalised healthcare. Finally, and perhaps most importantly, all but two studies (see overleaf) measured prescribing from electronic databases based on naturalistic observational data and thus no information was available on patient v. prescriber influences on low receipt of necessary medication.

FIG. 2 Prescribing differences for severe mental illness v. no mental illness: summary meta-analysis plot (random effects).

ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; HAART, highly active antiretroviral therapy; HRT, hormone replacement therapy; IHD, ischaemic heart disease.

FIG. 3 Prescribing differences for affective disorder v. no mental illness: summary meta-analysis plot (random effects).

ACE, angiotensin-converting enzyme inhibitor; HAART, highly active antiretroviral therapy.

FIG. 4 Prescribing differences for other mental illnessa v. no mental illness: summary meta-analysis plot (fixed effects).

ACE, angiotensin-converting enzyme inhibitor; HAART, highly active antiretroviral therapy.

a. Other mental illness includes any type of mental ill health other than pure affective disorder, severe mental illness or schizophrenia.

Possible explanations for suboptimal prescribing

It is already widely known that people with mental ill health have problems with psychotropic medication adherence. Reference Mitchell62,Reference Mitchell and Selmes63 This also applies to adherence to physical health medications. Reference DiMatteo, Lepper and Croghan64Reference Katon, Russo, Lin, Heckbert, Karter and Williams66 However, the studies reviewed here measure medication prescribing according to notations in medication databases (with the exception of Bishop et al who used notations in medical notes Reference Bishop, Alexander, Lund and Klepser39 and Suvisaari et al who used patient-reported medication at interview Reference Suvisaari, Jonna Perälä, Saarni, Kattainen, Lönnqvist and Reunanen56 ). Thus, uptake of medication and adherence to medication was not measured. We suggest therefore that the amount of medication actually taken as directed was probably less than that recorded here, and actual disparities in medication consumption may be more severe than disparities in prescribing. That said, some studies have found no difference or higher medication adherence to psychotropic drugs compared with physical health medication. Reference Piette, Heisler, Ganoczy, McCarthy and Valenstein67,Reference Himelhoch, Brown, Walkup, Chander, Korthius and Afful68 It may be important to acknowledge that insurance coverage influences uptake of medication in the USA and Canada. Reference Mulvale and Hurley69 However, the studies here do not measure uptake but rather prescribing. As many people with mental illness are unaware of their formal medical diagnosis and uninformed about their physical health medication, Reference Suvisaari, Jonna Perälä, Saarni, Kattainen, Lönnqvist and Reunanen56 we suggestthatthe disparitiesnoted are more likely to relate to physician habits than patient preferences.

TABLE 1 Overview of meta-analytic resultsFootnote a

Severe mental illness/schizophrenia Affective disorder Other mental illnessFootnote b
OR (95% CI) Z P I 2, % (95% CI) OR (95% CI) Z P I 2, % (95% CI) OR (95% CI) Z P I 2, % (95% CI)
All classes 0.74 (0.63–0.86) –3.83 0.001 97.2 (96.9–97.5) 0.75 (0.55–1.02) –1.82 0.07 94.6 (92.9–95.8) 0.95 (0.92–0.98) –3.07 0.002 64.5 (21.4–79.3)
ACEs or ARBs 0.89 (0.81–0.98) –2.31 0.021 74 (18.6–86.8) Insufficient data 0.92 (0.85–0.99)Footnote c –2.27 0.02 0 (0–72.9)
Anticoagulant (including aspirin) 0.99 (0.96–1.03) –0.67 0.500 3.4 (0–57.8) Insufficient data Insufficient data
Beta-blockers 0.90 (0.84–0.96) –3.2 0.001 63.1 (0–81.8) 0.76 (0.45–1.29) –1.01 0.3134 93.5 (83.7–96.3) Insufficient data
Anticholesterol drugs 0.59 (0.33–1.06) –1.75 0.08Footnote d 98.7 (98.4–98.9) 0.92 (0.64–1.32) –0.46 0.6469 77.2 (0–89.7) Insufficient data
HIV HAART medication Insufficient data Insufficient data 0.98 (0.75–1.28) –0.164 0.8693 82.6 (36–91.5)

ACEs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; HAART, highly active antiretroviral therapy.

a. Analysis: Z-test: test that odds ratio differs from 1; I 2, inconsistency: <80% equals low >80% equals high.

b. Other mental illness includes any type of mental ill health other than pure affective disorder, severe mental illness or schizophrenia.

c. Fixed-effects odds ratio.

d. Significant for statins alone.

Where physical health medication is prescribed by mental health professionals several factors may influence underprescribing. Previous work has shown that mental health professionals often miss physical conditions in their patients Reference Koranyi26,Reference Felker, Yazell and Short70,Reference Koran, Sox, Marton, Moltzen, Sox and Kraemer71 and undertake physical examinations in less than 50% of their patients. Reference Bobes, Alegría, Saiz-Gonzalez, Barber, Pérez and Saiz-Ruiz72 Mental health professionals often do not feel confident in prescribing physical health medication. Yet in the majority of cases physical health medication is prescribed by physicians in primary care, internal medicine and related medical specialties. We already know that mental health status and prescription of antipsychotics reduces likelihood of medical monitoring (such as glycated haemoglobin (HBA1c) testing). Reference Mitchell, Malone and Carney Doebbeling6,Reference Banta, Morrato, Lee and Haviland73 Primary care physicians often consider such patients to be ‘difficult to manage’, although many primary care physicians are willing to help with physical healthcare. Reference Lester, Tritter and Sorohan74,Reference Oud, Schuling, Slooff, Groenier, Dekker and Meyboom-de Jong75 Where primary care physicians lack expertise in mental health they are less likely to offer general care to those with mental illness. Reference Fleury, Bamvita and Tremblay76 Similarly when people with mental illness attend emergency departments they are less likely to be offered hospital care than other people. Reference Sullivan, Han, Moore and Kotrla77 In general practice, cardiovascular risk factors are often recorded in the medical records for adults with long-term mental illness, but primary care physicians appear reluctant to intervene. Reference Kendrick78 Clinician factors such as willingness to investigate, ability and enthusiasm to treat and willingness to offer follow-up are important predictors of quality of care. Because of medical and psychiatric comorbidity, seemingly unrelated conditions compete for clinicians’ attention. Reference Piette and Kerr79 Against this, studies suggest that the adequacy of medical care may not be adversely influenced by the number of comorbid medical disorders. Reference Min, Wenger, Fung, Chang, Ganz and Higashi80,Reference Higashi, Wenger, Adams, Fung, Roland and McGlynn81 Indeed, some have found that comorbidity favours superior care by virtue of higher than average healthcare visits. Reference Kurdyak and Gnam82 Indirect evidence suggests that clinicians’ attitudes towards patients directly influence health outcomes. In one study in primary care, poor mental health status was linked with poor accessibility, poorer general practitioner attitude and less time spent with the general practitioner. Reference Al-Mandhari, Hassan and Haran83 In a study of 59 patients seen in a US community mental health centre, 14% reported that they used the medical emergency department for their routine medical care needs and 45% said that their mental health provider did not ask them about medical issues. Reference Levinson Miller, Druss, Dombrowski and Rosenheck84

Three mitigating factors might explain low physician prescribing of physical health medication namely cautious prescribing, deferred prescribing and low patient acceptance of suggested medication. Regarding intentionally cautious prescribing, physicians’ prescription of cardiovascular medication may be cautious in light of possible links with suicide. Reference Reith and Edmonds85 Most plausibly this could apply to cholesterol-lowering agents, Reference Muldoon, Manuck, Mendelsohn, Kaplan and Belle86,Reference Lester87 beta-blockers Reference Sorensen, Mellemkjaer and Olsen88 and angiotensin-receptor antagonists. Reference Callréus, Agerskov Andersen, Hallas and Andersen89 Less likely but theoretically possible, physicians might be cautious about using aspirin together with selective serotonin reuptake inhibitors due to gastrointestinal bleeding, and ACE inhibitors and beta-blockers in people with mental illness who smoke. A second possibility is that treatment in some circumstances is deferred rather than omitted, although evidence suggests that in the context of mental illness most deferred treatment is not received at a later date. Reference Evon, Verma, Dougherty, Batey, Russo and Zacks90 A third hypothesis underlying inadequate prescriptions is low uptake of care on account of patient preference. It is not yet clear if this is the primary explanation. Reference Cradock-O'Leary, Young, Yano, Wang and Lee91Reference Folsom, McCahill, Bartels, Lindamer, Ganiats and Jeste93 For example, Salsberry and colleagues (2005) found that compared with the general population, those with severe mental illness had more emergency department visits and visited a doctor more frequently, but despite this high healthcare utilisation had very low rates of cervical smears and mammograms. Reference Salsberry, Chipps and Kennedy94 People with mental ill health perceive barriers to accessing primary physical healthcare. Reference Levinson Miller, Druss, Dombrowski and Rosenheck84,Reference Dickerson, McNary, Brown, Kreyenbuhl, Goldberg and Dixon92,Reference Crews, Batal, Elasy, Casper and Mehler95Reference Bradford, Kim, Braxton, Marx, Butterfield and Elbogen97 Patients often cite lack of availability of medical advice and poor quality of medical advice as influential. Reference Levinson Miller, Druss, Dombrowski and Rosenheck84,Reference Druss and Rosenheck98,Reference O'Day, Killeen, Sutton and Iezzoni99 Observational evidence shows many have difficulty getting timely access to appropriate primary healthcare. Reference Farmer27,Reference Bradford, Kim, Braxton, Marx, Butterfield and Elbogen97,Reference Rice and Duncan100,Reference Chwastiak, Rosenheck and Kazis101 For example, data from the 1999 Large Health Survey of Veterans found that veterans with schizophrenia, bipolar disorder or a drug use disorder were less likely to have had any primary care visit than those without these diagnoses, even after controlling for medical comorbidity. Reference Chwastiak, Rosenheck and Kazis101

Intervention to improve therapeutic care

Assuming these disparities in prescribing are robust, what can be done to improve quality of medical care? Druss & von Esenwein (2006) Reference Druss and von Esenwein102 reviewed six randomised trials designed to improve medical care in psychiatric conditions. These studies demonstrated a substantial positive impact on linkage to and quality of medical care albeit with a diverse range of interventions. One study showed that a simple intervention could improve readiness to begin HAART. Reference Balfour, Kowal, Silverman, Tasca, Angel and Macpherson103 Ismail et al and Winkley et al pooled 46 trials regarding the effect of psychological treatment on glycaemic control but showed only very modest effects in adults. Reference Ismail, Winkley and Rabe-Hesketh104,Reference Winkley, Landau, Eisler and Ismail105 Anderson et al (1998) reported a meta-analysis of 43 studies involving strategies to improve the delivery of preventive care that could hold valuable lessons. Reference Anderson, Janes and Jenkins106 In general, interventions were moderately effective in improving immunisation, screening and counselling. Reference Anderson, Janes and Jenkins106 In this data-set, two studies examined the effect of antidepressant treatment on HAART utilisation in patients with depression. Tegger et al (2008) found that untreated patients were 40% as likely to receive HAART; in treated patients there was no significant difference. Reference Tegger, Crane, Tapia, Uldall, Holte and Kitahata57 Similarly, Cook et al found that mental health treatment increased the probability of self-reported HAART use. Reference Cook, Grey, Burke-Miller, Cohen and Anastos32 Primary care physician recommendation of screening has been shown to be one of the strongest predictors of receipts of screening. Reference Friedman, Neff, Webb and Latham107Reference Friedman, Puryear, Moore and Green110 Better communication between primary care providers and specialist mental health services might improve prescribing for mental and physical ill health. Reference Oud, Schuling, Slooff, Groenier, Dekker and Meyboom-de Jong75,Reference Phelan, Stradins and Morrison111 However, in a trial of an integrated model of care for older people, the intervention helped with access but did not produce any significant treatment effects for depression or anxiety. Reference Arean, Ayalon, Jin, McCulloch, Linkins and Chen112

From a research perspective, a detailed examination of patient and provider influences on received medication is urgently needed. Clinically, we suggest that treatment of comorbid physical conditions is prioritised in patients with mental health concerns and closely monitored. Reference Dickinson, Dickinson, Rost, DeGruy, Emsermann and Froshaug113 Clinicians caring for patients with physical and mental illness should take particular care to ensure optimal treatment is maintained in both areas. At an organisation level, monitoring systems are needed to ensure that the medical care of people with mental ill health is not overlooked.


We thank David Ferguson for helping with the extraction of quality appraisal of primary studies.


Declaration of interest



1 Unützer, J, Schoenbaum, M, Druss, BG, Katon, WJ. Transforming mental health care at the interface with general medicine: report for the Presidents Commission. Psychiatr Serv 2006; 57: 3747.Google Scholar
2 De Hert, M, Dekker, JM, Wood, D, Kahl, KG, Holt, RI, Möller, HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009; 24: 412–24.CrossRefGoogle Scholar
3 National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update). NICE, 2011 ( Scholar
4 Fleischhacker, WW, Cetkovich-Bakmas, M, De Hert, M, Hennekens, CH, Lambert, M, Leucht, S, et al. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry 2008; 69: 514–9.Google ScholarPubMed
5 Ruiz, JS, Garcia, JB, Ruiloba, JV, Giner Ubago, J, Garc$lAa-Portilla González, MP. Consensus on physical health of patients with schizophrenia from the Spanish Societies of Psychiatry and Biological Psychiatry [in Spanish]. Actas Esp De Psiquiatr 2008; 36: 251–64.Google Scholar
6 Mitchell, AJ, Malone, D, Carney Doebbeling, C. Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparative studies. Br J Psychiatry 2009; 194: 491–9.Google Scholar
7 Roberts, L, Roalfe, A, Wilson, S, Lester, N. Physical health care of patients with schizophrenia in primary care: a comparative study. Fam Pract 2007; 24: 3440.Google Scholar
8 Vahia, IV, Diwan, S, Bankole, AO, Kehn, M, Nurhussein, M, Ramirez, P, et al. Adequacy of medical treatment among older persons with schizophrenia. Psychiatr Serv 2008; 59: 853–9.CrossRefGoogle ScholarPubMed
9 Desai, MM, Rosenheck, RA, Druss, BG, Perlin, JB. Mental disorders and quality of diabetes care in the veterans health administration. Am J Psychiatry 2002; 159: 1584–90.Google Scholar
10 Mateen, FJ, Jatoi, A, Lineberry, TW, Aranguren, D, Creagan, ET, Croghan, GA, et al. Do patients with schizophrenia receive state-of-the-art lung cancer therapy? A brief report. Psychooncology 2008; 17: 721–5.Google Scholar
11 Li, Y, Glance, LG, Cai, X, Mukamel, DB. Adverse hospital events for mentally-ill patients undergoing coronary artery bypass surgery. Health Serv Res 2008; 43: 2239–52.CrossRefGoogle ScholarPubMed
12 Copeland, LA, Zeber, JE, Pugh, MJ, Mortensen, EM, Restrepo, MI, Lawrence, VA. Postoperative complications in the seriously mentally ill - a systematic review of the literature. Ann Surgery 2008; 248: 31–8.Google Scholar
13 Saha, S, Chant, D, McGrath, J. A systematic review of mortality in schizophrenia - is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64: 1123–31.Google Scholar
14 Prince, M, Patel, V, Saxena, S, Maj, M, Maselko, J, Phillips, MR, et al. No health without mental health. Lancet 2007; 370: 859–77.Google Scholar
15 Mitchell, AJ, Malone, D. Physical health and schizophrenia. Curr Opin Psychiatry 2006; 19: 432–7.Google Scholar
16 Carney, CP, Jones, L, Woolson, RF. Medical comorbidity in women and men with schizophrenia: a population-based controlled study. J Gen Intern Med 2006; 21: 1133–7.CrossRefGoogle ScholarPubMed
17 Weber, NS, Cowan, DN, Millikan, AM, Niebuhr, DW. Psychiatric and general medical conditions comorbid with schizophrenia in the national hospital discharge survey. Psychiatr Serv 2009; 60: 1059–67.Google Scholar
18 Perron, BE, Howard, MO, Nienhuis, JK, Bauer, MS, Woodward, AT, Kilbourne, AM. Prevalence and burden of general medical conditions among adults with bipolar I disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2009; 79: 1407–15.Google Scholar
19 Kisely, S, Simon, G. An international study of the effect of physical ill health on psychiatric recovery in primary care. Psychosom Med 2005; 67: 116–22.Google Scholar
20 Zolnierek, CD. Non-psychiatric hospitalization of people with mental illness: systematic review. J Adv Nurs 2009; 65: 1570–83.Google Scholar
21 Chwastiak, L, Rosenheck, R, Leslie, D. Impact of medical comorbidity on the quality of schizophrenia pharmacotherapy in a national VA sample. Med Care 2006; 44: 5561.Google Scholar
22 Mackell, JA, Harrison, DJ, McDonnell, DD. Relationship between preventative physical health care and mental health in individuals with schizophrenia: a survey of caregivers. Ment Health Serv Res 2005; 7: 225–8.Google Scholar
23 Lord, O, Mitchell, AJ, Malone, D. Receipt of preventive medical care and medical screening for patients with mental illness: a comparative analysis. Gen Hosp Psychiatry 2010; 32: 519–43.Google Scholar
24 Amaddeo, F, Barbui, C, Perini, G, Biggeri, A, Tansella, M. Avoidable mortality of psychiatric patients in an area with a community-based system of mental health care. Acta Psychiatr Scand 2007; 115: 320–5.CrossRefGoogle Scholar
25 Kilbourne, AM, McCarthy, JF, Welsh, D, Blow, F. Recognition of co-occurring medical conditions among patients with serious mental illness. J Nerv Ment Dis 2006; 194: 598602.Google Scholar
26 Koranyi, E. Morbidity and rate of undiagnosed physical illness in a psychiatric population. Arch Gen Psychiatry 1979; 36: 414–9.Google Scholar
27 Farmer, S. Medical problems of chronic patients in a community support program. Psychiatr Serv 1987; 38: 745–9.Google Scholar
28 Fallow, S, Bowler, C, Dennis, M, Jones, P. Undetected physical illness in older referrals to a community mental-health-service. Int J Geriatr Psychiatry 1995; 10: 74–5.Google Scholar
29 Bernardo, M, Banegas, JR, Canas, F, Casademot, X, Riesgo, Y, Varela, C. Low level of medical recognition and treatment of cardiovascular risk factors in patients with schizophrenia in Spain. 13th Biennial Winter Workshop on Schizophrenia Research. Schizophr Res 2006; 81 (suppl): 176–7Google Scholar
30 Desai, MM, Rosenheck, RA. Unmet need for medical care among homeless adults with serious mental illness. Gen Hosp Psychiatry 2005; 27: 418–25.Google Scholar
31 Muther, J, Abholz, HH, Wiese, B, Fuchs, A, Wollny, A, Pentzek, M. Are patients with dementia treated as well as patients without dementia for hypertension, diabetes, and hyperlipidaemia? Br J Gen Pract 2010; 60: 671–4.CrossRefGoogle ScholarPubMed
32 Cook, JA, Grey, D, Burke-Miller, J, Cohen, MH, Anastos, K. Effects of treated and untreated depressive symptoms on highly active antiretroviral therapy use in a US multi-site cohort of HIV-positive women. AIDS Care 2006; 18: 93100.Google Scholar
33 Wells, GA, Shea, B, O'Connell, D, Peterson, J, Welch, V, Losos, M, Tugwell, P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses. Ottawa Hospital Research Institute, 2011 ( Scholar
34 Moher, D, Liberati, A, Tetzlaff, J, Altman, DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.Google Scholar
35 Zhang, JM, Yu, KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998; 280: 1690–1.Google Scholar
36 Higgins, JPT, Thompson, SG, Deeks, JJ, Altman, DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–60.Google Scholar
37 Peters, JL, Sutton, AJ, Jones, DR, Abrams, KR, Rushton, L. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006; 295: 676–80.Google Scholar
38 Baxter, JD, Samnaliev, M, Clark, RE. The quality of asthma care among adults with substance-related disorders and adults with mental illness. Psychiatr Serv 2009; 60: 43–9.CrossRefGoogle ScholarPubMed
39 Bishop, JR, Alexander, B, Lund, BC, Klepser, TB. Osteoporosis screening and treatment in women with schizophrenia: a controlled study. Pharmacotherapy 2004; 24: 515–21.Google Scholar
40 Blecker, S, Zhang, Y, Ford, DE, Guallar, E, Dosreis, S, Steinwachs, DM, et al. Quality of care for heart failure among disabled Medicaid recipients with and without severe mental illness. Gen Hosp Psychiatry 2010; 32: 255–61.Google Scholar
41 Bogart, LM, Fremont, AM, Young, AS, Pantoja, P, Chinman, M, Morton, S, et al. Patterns of HIV care for patients with serious mental illness. AIDS Patient Care STDS 2006; 20: 175–82.Google Scholar
42 Chander, G, Himelhoch, S, Fleishman, JA, Hellinger, J, Gaist, P, Moore, RD, et al. HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use. AIDS Care 2009; 21: 655–63.Google Scholar
43 Desai, MM, Rosenheck, RA, Druss, BG, Perlin, JB. Mental disorders and quality of care among postacute myocardial infarction outpatients. J Nerv Ment Dis 2002; 190: 51–3.Google Scholar
44 Druss, BG, Bradford, WD, Rosenheck, RA, Radford, MJ, Krumholz, HM. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry 2001; 58: 565–72.Google Scholar
45 Goodwin, JS, Zhang, DD, Ostir, GV. Effect of depression on diagnosis, treatment, and survival of older women with breast cancer. J Am Geriatr Soc 2004; 52: 106–11.Google Scholar
46 Himelhoch, S, Moore, RD, Treisman, G, Gebo, KA. Does the presence of a current psychiatric disorder in AIDS patients affect the initiation of antiretroviral treatment and duration of therapy? J Acquir Immune Defic Syndr 2004; 37: 1457–63.Google Scholar
47 Himelhoch, S, Chander, G, Fleishman, JA, Hellinger, J, Gaist, P, Gebo, KA, et al. Access to HAART and utilization of inpatient medical hospital services among HIV-infected patients with co-occurring serious mental illness and injection drug use. Gen Hosp Psychiatry 2007; 29: 518–25.Google Scholar
48 Hippisley-Cox, J, Parker, C, Coupland, C, Vinogradova, Y. Inequalities in the primary care of patients with coronary heart disease and serious mental health problems: a cross-sectional study. Heart 2007; 93: 1256–62.Google Scholar
49 Kisely, S, Campbell, LA, Wang, Y. Treatment of ischaemic heart disease and stroke in individuals with psychosis under universal healthcare. Br J Psychiatry 2009; 195: 545–50.Google Scholar
50 Kreyenbuhl, J, Dickerson, F, Medoff, D, Brown, CH, Goldberg, RW, Fang, L, et al. Extent and management of cardiovascular risk factors in patients with type 2 diabetes and serious mental illness. J Nerv Ment Dis 2006; 194: 404–10.Google Scholar
51 Mijch, A, Burgess, P, Judd, F, Grech, P, Komiti, A, Hoy, J, et al. Increased health care utilization and increased antiretroviral use in HIV-infected individuals with mental health disorders. HIV Med 2006; 7: 205–12.CrossRefGoogle ScholarPubMed
52 Petersen, LA, Normand, SL, Druss, BG, Rosenheck, RA. Process of care and outcome after acute myocardial infarction for patients with mental illness in the VA health care system: are there disparities? Health Serv Res 2003; 38: 4163.Google Scholar
53 Plomondon, ME, Michael Ho, PM, Wang, L, Greiner, GT, Shore, JH, Sakai, JT, et al. Severe mental illness and mortality of hospitalized ACS patients in the VHA. BMC Health Serv Res 2007; 7: 146.Google Scholar
54 Rathore, SS, Wang, Y, Druss, BG, Masoudi, FA, Krumholz, HM. Mental disorders, quality of care, and outcomes among older patients hospitalized with heart failure: an analysis of the national heart failure project. Arch Gen Psychiatry 2008; 65: 1402–8.CrossRefGoogle ScholarPubMed
55 Redelmeier, D, Tan, SH, Booth, GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Eng J Med 1998; 338: 1516–20.CrossRefGoogle ScholarPubMed
56 Suvisaari, J, Jonna Perälä, J, Saarni, SI, Kattainen, A, Lönnqvist, J, Reunanen, A. Coronary heart disease and cardiac conduction abnormalities in persons with psychotic disorders in a general population. Psychiatry Res 2010; 175: 126–32.Google Scholar
57 Tegger, MK, Crane, HM, Tapia, KA, Uldall, KK, Holte, SE, Kitahata, MM. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDS 2008; 22: 233–43.Google Scholar
58 Wang, PS, Avorn, J, Brookhart, MA, Mogun, H, Schneeweiss, S, Fischer, MA, et al. Effects of noncadiovascular comorbidities on antihypertensive use in elderly hypertensives. Hypertension 2005; 46: 273–9.Google Scholar
59 Weiss, AP, Henderson, DC, Weilburg, JB, Goff, DC, Meigs, JB, Cagliero, E, et al. Treatment of cardiac risk factors among patients with schizophrenia and diabetes. Psychiatr Serv 2006; 57: 1145–52.Google Scholar
60 Yun, LW, Maravi, M, Kobayashi, JS, Barton, PL, Davidson, AJ. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. J Acquir Immune Defic Syndr 2005; 38: 432–8.CrossRefGoogle ScholarPubMed
61 Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603–5.Google Scholar
62 Mitchell, AJ. High medication discontinuation rates in psychiatry: how often is it understandable? J Clin Psychopharmacol 2006; 26: 109–12.Google Scholar
63 Mitchell, AJ, Selmes, T. Why don't patients take their medicine? Reasons and solutions in psychiatry. Adv Psychiatr Treat 2007; 13: 336–46.CrossRefGoogle Scholar
64 DiMatteo, MR, Lepper, HS, Croghan, TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 2101–7.CrossRefGoogle ScholarPubMed
65 Gonzalez, JS, Peyrot, M, McCarl, LA, Collins, EM, Serpa, L, Mimiaga, MJ, et al. Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care 2008; 31: 2398–403.Google Scholar
66 Katon, W, Russo, J, Lin, EH, Heckbert, SR, Karter, AJ, Williams, LH, et al. Diabetes and poor disease control: is comorbid depression associated with poor medication adherence or lack of treatment intensification? Psychosom Med 2009; 71: 965–72.Google Scholar
67 Piette, JD, Heisler, M, Ganoczy, D, McCarthy, JF, Valenstein, M. Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension. Psychiatr Serv 2007; 58: 207–12.Google Scholar
68 Himelhoch, S, Brown, CH, Walkup, J, Chander, G, Korthius, PT, Afful, J, et al. HIV patients with psychiatric disorders are less likely to discontinue HAART. AIDS 2009; 23: 1735–42.Google Scholar
69 Mulvale, G, Hurley, J. Insurance coverage and the treatment of mental illness: effect on medication and provider use. J Ment Health Policy Econ 2008; 11: 177–99.Google Scholar
70 Felker, B, Yazell, JJ, Short, D. Mortality and medical comorbidity among psychiatric patients: a review. Psychiatr Serv 1996; 47: 1356–63.Google Scholar
71 Koran, LM, Sox, HC, Marton, KI, Moltzen, S, Sox, CH, Kraemer, HC, et al. Medical evaluation of psychiatric patients. 1. Results in a state mental health system. Arch Gen Psychiatry 1989; 46: 733–40.CrossRefGoogle Scholar
72 Bobes, J, Alegría, AA, Saiz-Gonzalez, MD, Barber, I, Pérez, JL, Saiz-Ruiz, J. Change in psychiatrists' attitudes towards the physical health care of patients with schizophrenia coinciding with the dissemination of the consensus on physical health in patients with schizophrenia. Eur Psychiatry 2011; 26: 305–11.Google Scholar
73 Banta, JE, Morrato, EH, Lee, SW, Haviland, MG. Retrospective analysis of diabetes care in California Medicaid patients with mental illness. J Gen Intern Med 2009; 24: 802–8.Google Scholar
74 Lester, H, Tritter, JQ, Sorohan, H. Patients‘ and health professionals’ views on primary care for people with serious mental illness: focus group study. BMJ 2005; 330: 1122.CrossRefGoogle ScholarPubMed
75 Oud, MJT, Schuling, J, Slooff, CJ, Groenier, KH, Dekker, JH, Meyboom-de Jong, B. Care for patients with severe mental illness: the general practitioner's role perspective. BMC Fam Pract 2009; 10: 29.Google Scholar
76 Fleury, MJ, Bamvita, JM, Tremblay, J. Variables associated with general practitioners taking on serious mental disorder patients. BMC Fam Pract 2009; 10: 41.Google Scholar
77 Sullivan, G, Han, X, Moore, S, Kotrla, K. Disparities in hospitalization for diabetes among persons with and without co-occurring mental disorders. Psychiatr Serv 2006; 57: 1126–31.Google Scholar
78 Kendrick, T. Cardiovascular and respiratory risk factors and symptoms among general practice patients with long-term mental illness. Br J Psychiatry 1996; 169: 733–9.CrossRefGoogle ScholarPubMed
79 Piette, JD, Kerr, EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care 2006; 29: 725–31.Google Scholar
80 Min, LC, Wenger, NS, Fung, C, Chang, JT, Ganz, DA, Higashi, T, et al. Multimorbidity is associated with better quality of care among vulnerable elders. Med Care 2007; 45: 480–8.Google Scholar
81 Higashi, T, Wenger, NS, Adams, JL, Fung, C, Roland, M, McGlynn, EA, et al. Relationship between number of medical conditions and quality of care. N Engl J Med 2007; 356: 2496–504.Google Scholar
82 Kurdyak, PA, Gnam, WH. Medication management of depression - the impact of comorbid chronic medical conditions. J Psychosom Res 2004; 57: 565–71.Google Scholar
83 Al-Mandhari, AS, Hassan, AA, Haran, D. Association between perceived health status and satisfaction with quality of care: evidence from users of primary health care in Oman. Fam Pract 2004; 21: 519–27.Google Scholar
84 Levinson Miller, C, Druss, BG, Dombrowski, EA, Rosenheck, RA. Barriers to primary medical care among patients at a community mental health center. Psychiatr Serv 2003; 54: 1158–60.Google Scholar
85 Reith, DM, Edmonds, L. Assessing the role of drugs in suicidal ideation and suicidality. CNS Drugs 2007; 21: 463–72.Google Scholar
86 Muldoon, MF, Manuck, SB, Mendelsohn, AB, Kaplan, JR, Belle, SH. Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials. BMJ 2001; 322: 11–5.Google Scholar
87 Lester, D. Serum cholesterol levels and suicide: a meta-analysis. Suicide Life Threat Behav 2002; 32: 333–46.Google Scholar
88 Sorensen, HT, Mellemkjaer, L, Olsen, JH. Risk of suicide in users of beta-adrenoceptor blockers, calcium channel blockers and angiotensin converting enzyme inhibitors. Br J Clin Pharmacol 2001; 52: 313–8.Google Scholar
89 Callréus, T, Agerskov Andersen, U, Hallas, J, Andersen, M. Cardiovascular drugs and the risk of suicide: a nested case-control study. Eur J Clin Pharmacol 2006; 63: 591–6.Google Scholar
90 Evon, DM, Verma, A, Dougherty, KA, Batey, B, Russo, M, Zacks, S, et al. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci 2007; 52: 3251–8.Google Scholar
91 Cradock-O'Leary, J, Young, AS, Yano, EM, Wang, M, Lee, ML. Use of general medical services by VA patients with psychiatric disorders. Psychiatr Serv 2002; 53: 874–8.Google Scholar
92 Dickerson, FB, McNary, SW, Brown, CH, Kreyenbuhl, J, Goldberg, RW, Dixon, LB. Somatic healthcare utilization among adults with serious mental illness who are receiving community psychiatric services. Med Care 2003; 41: 560–70.Google Scholar
93 Folsom, DP, McCahill, M, Bartels, SJ, Lindamer, LA, Ganiats, TG, Jeste, DV. Medical comorbidity and receipt of medical care by older homeless people with schizophrenia or depression. Psychiatr Serv 2002; 53: 1456–60.Google Scholar
94 Salsberry, PJ, Chipps, E, Kennedy, C. Use of general medical services among medicaid patients with severe and persistent mental illness. Psychiatr Serv 2005; 56: 458–62.Google Scholar
95 Crews, C, Batal, H, Elasy, T, Casper, E, Mehler, PS. Primary care for those with severe and persistent mental illness. West J Med 1998; 169: 245–50.Google Scholar
96 Drapalski, AL, Milford, J, Goldberg, RW, Brown, CH, Dixon, LB, et al. Perceived barriers to medical care and mental health care among veterans with serious mental illness. Psychiatr Serv 2008; 59: 921–4.Google Scholar
97 Bradford, DW, Kim, MM, Braxton, LE, Marx, CE, Butterfield, M, Elbogen, EB. Access to medical care among persons with psychotic and major affective disorders. Psychiatr Serv 2008; 59: 847–52.Google Scholar
98 Druss, BG, Rosenheck, RA. Mental disorders and access to medical care in the United States. Am J Psychiatry 1998; 155: 1775–7.Google Scholar
99 O'Day, B, Killeen, MB, Sutton, J, Iezzoni, LI. Primary care experiences of people with psychiatric disabilities: barriers to care and potential solutions. Psychiatr Rehabil J 2005; 28: 339–45.Google Scholar
100 Rice, C, Duncan, DF. Alcohol use and reported physician visits in older adults. Prev Med 1995; 24: 229–34.Google Scholar
101 Chwastiak, LA, Rosenheck, RA, Kazis, LE. Utilization of primary care by veterans with psychiatric illness in the national department of veterans affairs health care system. J Gen Int Med 2008; 23: 1835–40.Google Scholar
102 Druss, BG, von Esenwein, SA. Improving general medical care for persons with mental and addictive disorders: systematic review. Gen Hosp Psychiatry 2006; 28: 145–53.Google Scholar
103 Balfour, L, Kowal, J, Silverman, A, Tasca, GA, Angel, JB, Macpherson, PA, et al. A randomized controlled psycho-education intervention trial: improving psychological readiness for successful HIV medication adherence and reducing depression before initiating HAART. AIDS Care 2006; 18: 830–8.Google Scholar
104 Ismail, K, Winkley, K, Rabe-Hesketh, S. Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes. Lancet 2004; 363: 1589–97.Google Scholar
105 Winkley, K, Landau, S, Eisler, I, Ismail, K. Psychological interventions to improve glycaemic control in patients with type 1 diabetes: systematic review and meta-analysis of randomised controlled trials. BMJ 2006; 333: 65.Google Scholar
106 Anderson, LA, Janes, GR, Jenkins, C. Implementing preventive services: to what extent can we change provider performance in ambulatory care? A review of the screening, immunization, and counseling literature. Ann Behav Med 1998; 20: 161–7.Google Scholar
107 Friedman, LC, Neff, NE, Webb, JA, Latham, CK. Early breast cancer detection behaviors among ethnically diverse low-income women. Psychooncology 1996; 5: 283–9.Google Scholar
108 Dodendorf, DM, Deogun, GK, Rodie, AR, Pol, LG. Assessing the patient's mammogram experience. Health Care Manage Rev 2004; 29: 7787.Google Scholar
109 Friedman, LC, Moore, A, Webb, JA, Puryear, LJ. Breast cancer screening among ethnically diverse low-income women in a general hospital psychiatry clinic. Gen Hosp Psychiatry 1999; 21: 374–81.Google Scholar
110 Friedman, L, Puryear, L, Moore, A, Green, CE. Breast and colorectal cancer screening among low income women with psychiatric disorders. Psychooncology 2005; 14: 786–91.Google Scholar
111 Phelan, M, Stradins, L, Morrison, S. Physical health of people with severe mental illness. BMJ 2001; 322: 443–4.Google Scholar
112 Arean, PA, Ayalon, L, Jin, C, McCulloch, CE, Linkins, K, Chen, H, et al. Integrated speciality mental health care among older minorities improves access but not outcomes: results of the PRISMe study. Int J Geriatr Psychiatry 2008; 23: 1086–92.Google Scholar
113 Dickinson, LM, Dickinson, WP, Rost, K, DeGruy, F, Emsermann, C, Froshaug, D, et al. Clinician burden and depression treatment: disentangling patient- and clinician-level effects of medical comorbidity. J Gen Intern Med 2008; 23: 1763–9.Google Scholar
Figure 0

FIG. 1 Quorom overview of search results.ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; HRT, hormone replacement therapy; HAART, highly active antiretroviral therapy. a. Classes usually combined by convention.

Figure 1

FIG. 2 Prescribing differences for severe mental illness v. no mental illness: summary meta-analysis plot (random effects).ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; HAART, highly active antiretroviral therapy; HRT, hormone replacement therapy; IHD, ischaemic heart disease.

Figure 2

FIG. 3 Prescribing differences for affective disorder v. no mental illness: summary meta-analysis plot (random effects).ACE, angiotensin-converting enzyme inhibitor; HAART, highly active antiretroviral therapy.

Figure 3

FIG. 4 Prescribing differences for other mental illnessav. no mental illness: summary meta-analysis plot (fixed effects).ACE, angiotensin-converting enzyme inhibitor; HAART, highly active antiretroviral therapy.a. Other mental illness includes any type of mental ill health other than pure affective disorder, severe mental illness or schizophrenia.

Figure 4

TABLE 1 Overview of meta-analytic resultsa

Supplementary material: PDF

Mitchell et al. supplementary material

Supplementary Material

Download Mitchell et al. supplementary material(PDF)
PDF 74.5 KB
Submit a response


No eLetters have been published for this article.